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Letters to the Editor
Changes in expression of transforming growth
factor beta mRNA isoforms in patients undergoing
tamoxifen therapy
Sir
The paperby MacCallum et al (1996) further investigates the role of
transforming growth factor beta (TGF-P) isoforms in breast
carcinogenesis and response to therapeutic intervention. Clinical
material was restricted to patients over 70 years of age with
oestrogen receptor (ER) positive tumours alledgedly at least 3 cm in
maximum diameter. This may limit the value of the study and any
conclusions drawn therefrom. Specific growth inhibitory effects of
TGF-3 are likely to be dependent upon stage ofdisease and may be
operative only in early breast cancer with modest tumour load
(Benson and Colletta, 1995). Presumably all these patients with
relatively large primary tumours (?.4 cm) were free ofovert meta-
stases (Anderson et al, 1989). No comment is made on the accuracy
of ultrasound alone in assessing tumour response and correlations
between sonographic and pathological response criteria.
This paper nonetheless does rather tantalisingly allude to mecha-
nisms for regulation of synthesis of individual TGF-0 isoforms in
response to anti-oestrogen therapy. Perry et al (1995) have recently
cited data suggesting a mechanistic dichotomy, with dominance of
post-transcriptional mechanisms at lower concentrations and tran-
scriptional control at higher concentrations of tamoxifen. The
present study provides further data in support ofdifferential regula-
tion. However, the authors appear diffident over whether they
consider the observed variations in levels of TGF-jI and TGF-P3
expression (which are statistically significant) to be a real effect or a
consequence ofa methodology that permits intratumoral assay vari-
ation ofup to 100%. In the Discussion section, it is stated that there
is no overall change in levels ofTGF-PI and TGF-f3 expression in
response to tamoxifen. Ifthere are in fact decreases in expression of
31 andP3 in some tumours but increases in others, it is inappropriate
to draw any conclusions on mechanisms of control without some
correlative data on corresponding changes in TGF-P protein.
Immunohistochemical studies on this group of patients would have
been useful; if levels of immunoreactive protein were to increase in
tumours demonstrating either an increase or a decrease in TGF-P
mRNA, then a complex interaction ofboth transcriptional and post-
transcriptional mechanisms is implicit. If there are no overall
changes in mRNA levels (with any apparent variations being attrib-
utable to experimental technique), then such results would be
consistent with previous studies, and our own unpublished observa-
tions suggestive of post-transcriptional regulation of TGF-f. Arrik
et al (1994) have reported the existence of two structurally distinct
forms ofTGF-f3 mRNA that display different rates oftranslational
efficiency. Hence, alteration in the balance of these represents a
further mechanism for controlling levels of protein synthesis inde-
pendently ofany overall quantitative changes in levels oftranscript.
Such issues introduce another dimension of complexity into the
elucidation and understanding of the role of TGF-P in both
neoplastic progression and mediation ofthe response to therapy.
Similarly, correlating changes in TGF-P2 mRNA expression
with both immunohistochemical as well as clinical studies is desir-
able. As pointed out by the authors, previous work from our labo-
ratory has demonstrated induction ofthe P1 isoform in response to
primary tamoxifen therapy, but no significant enhancement of
TGF-P2 was observed in either stromal orepithelial compartments
irrespective ofER status (Butta et al, 1992). Interestingly, we have
found significantly higher levels of TGF-,2 secretion in condi-
tioned media of fibroblasts derived from benign rather than
malignant breast tumours (Benson et al, 1996a). Malignant trans-
formation may be associated with a selective reduction in 32
isoform expression which could be restored by pharmacological
manipulation.
In situ hybridization studies have yielded mixed results; while
some have shown epithelial cells to be the prime source ofTGF-1
(cited therein), others have indicated that TGF-1 is located
predominantly in the stromal compartment of primary breast
tumours (Dalal et al, 1993; Kong et al, 1995). Failure to demon-
strate increases in TGF-1 expression in responsive tumours could
be a consequence of exhaustion of stromal induction ofTGF-,B in
these larger tumours with attenuation ofnegative paracrine effects.
Larger more advanced tumours may exhibit epithelial expression
ofTGF-1, but this is more likely to be destined to promote stromal
expansion rather than induce regression/apoptosis in these self-
same cells (Benson et al, 1996b). Response of larger tumours to
antioestrogens may principally involve classical ER-mediated
effects. Functional redundancy amongst growth factors could
undermine the influence ofTGF-f as a negative growth modulator
in this setting, with a poor correlation between clinical response
and expression of TGF-,B. Indeed, expression ofTGF-1 in epithe-
lial cells could be suppressed as a secondary phenomenon to
hinder stromal/angiogenic support and favour tumour regression.
JR Benson andAA Colletta
Department ofSurgery,
Chelsea and Westminster Hospital,
369 Fulham Road,
London SWIO 9NH, UK
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Changes in expression of transforming growth factor
beta mRNA isoforms in patients undergoing tamoxifen
therapy
Reply to the letter from Benson and Colletta
Sir
The controversy surrounding the complex role of transforming
growth factor (TGF-P) in breast cancer is once again highlighted
in the letter of Mr JR Benson and Dr AA Colletta. The comments
made are informative and, while we would concur with many of
them, we feel that some additional response is appropriate to
clarify some ofthe issues raised.
First of all, it is important to emphasize that the aim of our study
was to determine the effect of tamoxifen on TGF-P expression in
breast cancers from patients whose tumours could be accurately
assessed for response to therapy. It was not a study to elucidate the
role ofTGF-P in carcinogenesis or to assess expression in different
stages of disease, although we have already published data on the
latter (MacCallum et al, 1994). Although the study is limited to a
definedgroupofpatients,this is an importantcohort,andone inwhich
we could obtain sequential samples of tumour and accurately assess
response of these same lesions to tamoxifen treatment (Incidentally,
the rationale forusing ultrasound as an accurate assessment oftumour
size has already been published by Forouhi et al, 1994).
Secondly, we believe we have correctly shown conservatism in
terms of attributing differences between sequential samples of the
same tumour to the effects oftamoxifen. It is essential that inherent
variations of methodology and tumour heterogeneity are assessed
and realistically taken into account. Having done this in the present
study, it was reassuring that, with regard toTGF-P2 not only was it
more likely for expression to be higher in tamoxifen-treated biop-
sies but also that this pattern was exclusive to responding tumours.
We have therefore been satisfied that these effects were mediated
by tamoxifen. However, the direction of effects of treatment on
TGF-f 1 were almost equally increases or decreases, and there was
no statistical difference in patterns between responders and non-
responders. We have therefore been reluctant to claim dogmati-
cally that these influences are caused by tamoxifen, despite a
degree ofchange exceeding that ofour controls.
Nevertheless, we have discussed the possibility that tamoxifen
might more commonly induce the expression of TGF-,B1 in breast
cancers, an effect which may not have been apparent in our study
fora variety ofreasons (MacCallum et al, 1996). The exhaustion of
stromal induction ofTGF-P, as suggested by JR Benson and AA
Colletta, is also possible. However, that the stroma is the primary
source ofTGF-P is controversial; both we and others have shown
thatTGF-P appears to be synthesized predominantly within epithe-
lial cells of breast cancers (Auvinen et al, 1995; MacCallum et al,
1995; Walker and Gallagher, 1995). This is not necessarily at odds
with the apparent increased staining of TGF-,B1 in stroma
following primary tamoxifen therapy, as reported by Butta et al
(1992), if the growth factor was synthesized and secreted by
epithelial cells, but sequestered by the stromal compartment.
Indeed, if tamoxifen causes the death of epithelial cells, there
might be an impression of upregulation in residual stroma. We
would agree however, that simultaneous measurements of TGF-,
protein and mRNA would give an additional dimension to these
studies. Our immunohistochemical investigations are currently
under way, and preliminary data suggest that both TGF-P1 and
TGF-P2 predominantly localize to the epithelium.
In vitro studies using cell lines and animal models have yielded
important understanding ofthe role ofTGF-P in breast cancer, but
ultimately it is necessary to look at appropriate clinical material.
Such translational studies can be difficult to perform and may
produce results that are subject to variable interpretation depending
on perspective. However, in carrying out the reported study, we
believe that we have not only generated meaningful results, but
have been objective in deriving our conclusions.
J MacCallum and WR Miller
ICRFMedical Oncology Unit, Western General Hospital
Edinburgh EH4 2XU, UK
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